The advancement of ProHema into later-stage development builds upon positive results from a Phase 1b single-center study, interactions with the U.S. Food and Drug Administration and refinements to the product manufacturing process.
http://www.newswire.ca/en/story/1078521/fate-therapeutics-initiates-phase-2-clinical-study-of-prohema-for-the-treatment-of-hematologic-malignancies
http://www.newswire.ca/en/story/1078521/fate-therapeutics-initiates-phase-2-clinical-study-of-prohema-for-the-treatment-of-hematologic-malignancies
No comments:
Post a Comment